FDA Advisory Panel Unanimously Recommends Moderna's mRNA Flu Vaccine

An FDA advisory committee has unanimously recommended approval for Moderna's mRNA-based influenza vaccine, mRNA-1010, for adults aged 50 and older. This 9-0 vote supports the clinical data, despite initial skepticism from FDA scientists. The recommendation is a key step towards potential FDA approval by August 2026, offering a vaccine with potentially faster strain reformulation capabilities.